Although the aligned pathway is central to our work, the benefits of improved collaboration between MHRA and NICE go beyond it. A recent example is aficamten, a new daily pill for people with ...

The benefits of the new Alzheimer’s drug lecanemab are too small to justify the costs, NICE said in draft guidance published today. Lecanemab (also called Leqembi and made by Eisai) is for slowing ...

This guideline has been updated and replaced by epilepsies in children, young people and adults ...

Digital technologies to support home monitoring of vision changes for people with advanced dry age-related macular degeneration: early-use assessment HTG781 17 September 2026 17 September 2026 ...

Evidence-based recommendation on trastuzumab deruxtecan (Enhertu) for treating HER2-low metastatic or unresectable breast cancer after chemotherapy in adults. This guidance updates and replaces NICE ...

Evidence Documents containing the evidence that was used to develop the recommendations. Supporting evidence Surveillance report 2024 exceptional surveillance of familial breast cancer: classification ...

This guideline covers general principles for prescribing and managing withdrawal from opioids, benzodiazepines, gabapentinoids, Z‑drugs and antidepressants in primary and secondary care. It does not ...

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...

This guideline has been updated and replaced by NICE rapid guideline on managing COVID-19 (NG191) ...

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years Technology appraisal guidance TA554 Published: 21 December 2018 ...

intermittently scanned continuous glucose monitoring. HCL systems are only recommended if they are procured at a cost-effective price agreed by the companies and NHS England, and implemented following ...